U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| Under the Paperwork Reduction Act of 1995, no persons are required to respon | id to a collection of information unless it | displays a valid OMB control number. |
|--|--|---|
| TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING | | Docket Number (Optional) |
| REJECTION OVER A PENDING SECOND | PPLICATION | REG 142C |
| | SE S | |
| In re Application of: Wong et al. | | |
| Application No.: 09/577,468 | 1 7 2003 ප් | |
| Filed: 24 May 2000 | | |
| For: Use of Modified Ciliary Neurotrophic Factor | I TRADEMARK | |
| The owner*, Regeneron Pharmaceuticals, Inc., of 100 percent in provided below, the terminal part of the statutory term of any part beyond the expiration date of the full statutory term defined disclaimer filed prior to the grant of any patent granted on perfiled on 03 December 1999, of any patent on the pending second granted on the instant application shall be enforceable only for a second application are commonly owned. This agreement runs binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not diapplication that would extend to the expiration date of the full patent granted on the second application, as shortened by an event that any such granted patent: expires for failure to pay a a court of competent jurisdiction, is statutorily disclaimed in we | atent granted on the instant app in 35 U.S.C. 154 and 173 as inding second Application Num and application. The owner herel and during such period that it ar is with any patent granted on the sclaim the terminal part of any statutory term as defined in 35 by terminal disclaimer filed prior maintenance fee, is held unen- thole or terminally disclaimed to | plication, which would extend a shortened by any terminal ber 09/454.380 by agrees that any patent so and any patent granted on the he instant application and is patent granted on the instant 5 U.S.C. 154 and 173 of any or to the patent grant, in the forceable, is found invalid by under 37 CFR 1.321, has all |
| claims canceled by a reexamination certificate, is reissued, or statutory term as shortened by any terminal disclaimer filed prio Check either box 1 or 2 below, if appropriate. | | ior to the expiration of its full |
| 1. For submissions on behalf of an organization (e.g., of etc.), the undersigned is empowered to act on behalf | corporation, partnership, univers f of the organization. | sity, government agency, |
| I hereby declare that all statements made herein of minformation and belief are believed to be true; and further that the false statements and the like so made are punishable by fine to the United States Code and that such willful false statements issued thereon. | hese statements were made with the made with | ith the knowledge that willful r Section 1001 of Title 18 of |
| • [7] | | |
| 2. The undersigned is an attorney or agent of record. SLUANG1 00000020 180650 09577468 110.00 DA | Valeka Sh Signature | Date 11/14/03 |
| | Valeta G | togg |
| | Typed or printed name | |
| | | |
| | 914-345- | 7400 |
| | Telephone Number | |
| Terminal disclaimer fee under 37 CFR 1.20(d) is included. | | |
| WARNING: Information on this form may become be included on this form. Provide credit card info | public. Credit card information and authorization on | on should not PTO-2038. |
| *Statement under 37 CFR 3.73(b) is required if terminal disclaimer Form PTO/SB/96 may be used for making this statement. See MI | r is signed by the assignee (owner) PEP § 324. | |

12/08/2003 01 FC:1814

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.